MedTrace Logo

A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491

NCT03062956 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2018-03-23

No results posted yet for this study

Summary

Up to 72 healthy volunteers will be given a single dose of MYK-491 or placebo and be monitored for safety and tolerability over a 7 day period.

Conditions

  • Dilated Cardiomyopathy

Interventions

DRUG

MYK-491 or placebo

Oral suspension

Sponsors & Collaborators

  • MyoKardia, Inc.

    lead INDUSTRY

Principal Investigators

  • Jason Lickliter, MD · Nucleus Network

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-16
Primary Completion
2017-11-28
Completion
2017-11-28
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03062956 on ClinicalTrials.gov